Grufity logoGrufity logo

Amgen Inc Stock Research

AMGN

234.57USD-0.33(-0.14%)Market Closed

Market Summary

USD234.57-0.33
Market Closed
-0.14%

AMGN Stock Price

AMGN RSI Chart

AMGN Valuation

Market Cap

125.3B

Price/Earnings (Trailing)

19.12

Price/Sales (Trailing)

4.76

EV/EBITDA

9.67

Price/Free Cashflow

14.26

AMGN Price/Sales (Trailing)

AMGN Profitability

EBT Margin

27.91%

Return on Equity

178.97%

Return on Assets

10.06%

Free Cashflow Yield

7.01%

AMGN Fundamentals

AMGN Revenue

Revenue (TTM)

26.3B

Revenue Y/Y

-0.1%

Revenue Q/Q

2.81%

AMGN Earnings

Earnings (TTM)

6.6B

Earnings Y/Y

-14.9%

Earnings Q/Q

-24.59%

Price Action

52 Week Range

221.77294.64
(Low)(High)

Last 7 days

2.8%

Last 30 days

-2.7%

Last 90 days

-11.7%

Trailing 12 Months

3.8%

AMGN Financial Health

Current Ratio

1.41

Debt/Equity

13.77

Debt/Cashflow

0.28

AMGN Investor Care

Dividend Yield

3.31%

Dividend/Share (TTM)

7.76

Buy Backs (1Y)

4.35%

Diluted EPS (TTM)

12.11

Peers (Alternatives to Amgen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
125.3B
26.3B
-2.75% 3.76%
19.12
4.76
1.32% 11.18%
99.6B
27.3B
-8.96% 41.01%
21.68
3.65
-0.09% -26.23%
58.4B
19.3B
-12.76% 1.00%
6.99
3.03
4.29% -31.47%
38.3B
10.2B
-9.67% 32.94%
12.57
3.76
-7.36% 95.80%
MID-CAP
9.1B
1.5B
-9.09% 3.35%
58.87
6.11
31.34% 72.43%
3.2B
108.5M
-21.10% -19.55%
-9.78
29.38
122.90% -12.19%
2.5B
60.9M
-18.47% -36.46%
-8.76
41.55
17.51% 22.00%
2.1B
107.9M
22.95% 67.45%
-4.29
19.27
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-14.86% -46.41%
-4.63
11.04
-70.76% -603.77%
1.1B
7.0M
-22.18% 24.65%
-7.11
158.97
131.81% -45.39%
541.9M
96.3M
-12.99% -82.24%
-1.92
5.63
72.44% -32.79%
513.7M
2.0B
-39.67% -92.01%
-0.78
0.26
72.89% 62.27%
355.3M
111.3M
-30.55% -58.78%
-1.85
3.19
0.54% -7.86%
101.4M
159.0K
-16.47% -82.96%
-0.97
637.62
-86.46% -64.56%
25.1M
-
94.03% -77.12%
-0.31
3.21
0.51% -185.61%

Financials for Amgen

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.0%26,32326,33026,38426,31625,979
  S&GA Expenses2.8%5,4145,2675,2855,3425,368
Costs and Expenses0.4%16,75716,69017,02618,30618,340
EBITDA-2.0%12,16912,41312,11711,124-
EBITDA Margin-1.9%0.46*0.47*0.46*0.42*-
Earnings Before Taxes-5.0%7,3467,7297,4926,5196,701
EBT Margin-4.9%0.28*0.29*0.28*0.25*-
Interest Expenses6.0%1,4061,3261,2541,2071,197
Net Income-4.1%6,5526,8356,5765,7235,893
Net Income Margin-4.1%0.25*0.26*0.25*0.22*-
Free Cahsflow-2.4%8,7858,9978,3558,417-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets2.2%65,12163,70059,29459,19661,165
  Current Assets-7.8%22,18624,06219,32218,52019,385
    Cash Equivalents-19.7%7,6299,5025,2036,5287,989
  Inventory3.6%4,9304,7574,5544,4114,086
  Net PPE4.6%5,4275,1885,1585,1425,184
  Goodwill4.6%15,52914,84514,86514,89714,890
  Current Liabilities9.5%15,68714,33112,61812,88612,184
  Long Term Debt-33,309----
    LT Debt, Current3.1%1,5911,54381784487.00
    LT Debt, Non Current0.5%37,35437,16135,70536,01033,222
Shareholder's Equity0.2%3,6613,6532,4199166,700
  Retained Earnings-2.0%-28,622-28,066-28,252-29,568-24,600
Shares Outstanding0.1%534534535534558
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-1.6%9,7219,8809,3209,3219,261
  Share Based Compensation17.6%401341---
Cashflow From Investing-115.8%-6,044-2,801-2,461941733
Cashflow From Financing57.7%-4,037-9,546-8,286-9,846-8,271
  Dividend Payments1.2%4,1964,1464,1074,0774,013
  Buy Backs-18.5%6,3607,8038,87210,4144,975

Risks for AMGN

What is the probability of a big loss on AMGN?

17.3%


Probability that Amgen stock will be more than 20% underwater in next one year

0%


Probability that Amgen stock will be more than 30% underwater in next one year.

0%


Probability that Amgen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AMGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Amgen was unfortunately bought at previous high price.

Drawdowns

Returns for AMGN

Cumulative Returns on AMGN

12.8%


10-Year Cumulative Returns

10.4%


7-Year Cumulative Returns

7.7%


5-Year Cumulative Returns

8.3%


3-Year Cumulative Returns

What are the long-term rolling returns for AMGN?

FIve years rolling returns for Amgen.

Annualized Returns

Which funds bought or sold AMGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-13.27
100,348
9,602,350
0.27%
2023-03-13
Claro Advisors LLC
added
15.86
85,755
427,755
0.14%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.89
41,664,100
310,811,000
0.34%
2023-03-10
MATHER GROUP, LLC.
reduced
-4.99
104,685
1,079,680
0.02%
2023-03-08
Capital Asset Advisory Services LLC
added
0.06
60,848
407,848
0.03%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
reduced
-0.02
498,674
3,523,670
0.55%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
added
0.49
397,586
2,718,590
0.17%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-2.67
8,583,000
72,555,000
0.36%
2023-03-03
TIAA, FSB
reduced
-4.78
2,393,810
24,249,800
0.10%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
22,157,100
22,157,100
0.27%

1–10 of 46

Latest Funds Activity

Are funds buying AMGN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own AMGN
No. of Funds

Amgen News

Bluefield Daily Telegraph

AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ....

Bluefield Daily Telegraph,
3 hours ago

Nasdaq

Nasdaq

StockNews.com

Schedule 13G FIlings of Amgen

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.01%
48,065,139
SC 13G/A
Feb 07, 2023
blackrock inc.
9.1%
48,513,079
SC 13G/A
Feb 06, 2023
state street corp
5.58%
29,760,088
SC 13G/A
Feb 11, 2022
capital research global investors
3.9%
22,157,906
SC 13G/A
Feb 10, 2022
state street corp
5.37%
30,221,708
SC 13G/A
Feb 09, 2022
vanguard group inc
8.28%
46,661,009
SC 13G/A
Feb 01, 2022
blackrock inc.
8.9%
50,046,345
SC 13G/A
Feb 16, 2021
capital research global investors
5.5%
31,762,327
SC 13G/A
Feb 10, 2021
vanguard group inc
8.11%
47,227,229
SC 13G/A
Feb 05, 2021
state street corp
5.17%
30,113,284
SC 13G

AMGN Fair Value

Amgen fair value in different scenarios

The table shows the Fair Value estimates for Amgen for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

109.17

-53.46%

132.66

-43.45%

169.25

-27.85%

258.30

10.12%

304.31

29.73%
Current Inflation

100.97

-56.96%

121.19

-48.34%

151.99

-35.20%

226.05

-3.63%

264.21

12.64%
Very High Inflation

90.72

-61.32%

107.13

-54.33%

131.32

-44.02%

188.71

-19.55%

218.22

-6.97%

Historical Amgen Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Amgen

View All Filings
Date Filed Form Type Document
Mar 09, 2023
8-K
Current Report
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading

Latest Insider Trading transactions for AMGN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-06
Griffith Peter H.
acquired
-
-
7,753
evp & cfo
2023-03-06
Louie Linda H.
acquired
-
-
387
vp, finance & cao
2023-03-06
Gordon Murdo
acquired
-
-
7,947
evp global commercial ops
2023-03-06
Grygiel Nancy A.
acquired
-
-
968
svp & cco
2023-03-06
Graham Jonathan P
acquired
-
-
7,560
evp, gen. counsel & secy.
2023-03-06
Santos Esteban
acquired
-
-
7,753
evp, operations
2023-03-06
REESE DAVID M
acquired
-
-
7,947
evp, research and development
2023-03-06
Khosla Rachna
acquired
-
-
687
svp, business development
2023-03-06
Bradway Robert A
acquired
-
-
27,915
chairman, ceo and president
2023-03-06
Miller Derek
acquired
-
-
920
svp, human resources

1–10 of 50

Robert A. Bradway
24200
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AMGN Income Statement

2022-12-31
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues:   
Total revenues$ 26,323$ 25,979$ 25,424
Operating expenses:   
Cost of sales6,4066,4546,159
Research and development4,4344,8194,207
Acquired in-process research and development01,5050
Selling, general and administrative5,4145,3685,730
Other503194189
Total operating expenses16,75718,34016,285
Operating income9,5667,6399,139
Interest expense, net(1,406)(1,197)(1,262)
Other (expense) income, net(814)259256
Income before income taxes7,3466,7018,133
Provision for income taxes794808869
Net income$ 6,552$ 5,893$ 7,264
Earnings per share:   
Basic (in usd per share)$ 12.18$ 10.34$ 12.40
Diluted (in usd per share)$ 12.11$ 10.28$ 12.31
Shares used in the calculation of earnings per share:   
Basic (in shares)538570586
Diluted (in shares)541573590
Product sales   
Revenues:   
Total revenues$ 24,801$ 24,297$ 24,240
Other revenues   
Revenues:   
Total revenues$ 1,522$ 1,682$ 1,184

AMGN Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 7,629$ 7,989
Marketable securities1,67648
Trade receivables, net5,5634,895
Inventories4,9304,086
Other current assets2,3882,367
Total current assets22,18619,385
Property, plant and equipment, net5,4275,184
Intangible assets, net16,08015,182
Goodwill15,52914,890
Other noncurrent assets5,8996,524
Total assets65,12161,165
Current liabilities:  
Accounts payable1,5721,366
Accrued liabilities12,52410,731
Current portion of long-term debt1,59187
Total current liabilities15,68712,184
Long-term debt37,35433,222
Long-term tax liabilities5,7576,594
Other noncurrent liabilities2,6622,465
Contingencies and commitments
Stockholders’ equity:  
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding—534.0 shares in 2022 and 558.3 shares in 202132,51432,096
Accumulated deficit(28,622)(24,600)
Accumulated other comprehensive loss(231)(796)
Total stockholders’ equity3,6616,700
Total liabilities and stockholders’ equity$ 65,121$ 61,165